alopecia

Finasteride (MK-906) is an oral inhibitor of active testosterone 5-alpha-reductase and Ki value is 10 nM.

Apoptosis Inhibitor was a novel inhibitor of programmed cell death associate with caspase-3 inhibition.

CRTh2 antagonist 2 is a selective and potent CRTH2 antagonist, IC50≤10 nM. CRTh2 antagonist 2 can be used to study the direction of androgenic alopecia.

Lapisteride (CS-891) a steroidal 5α-reductase inhibitor is used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia and may be effective in preventing or treating AGA .

Wnt pathway activator 1 is a potent Wnt activator with an IC50 of 28-29 nM. Wnt pathway activator 1 is a potent Wnt activator for the treatment of androgenetic alopecia (AGA).

Alpha-Estradiol (Epiestradiol) is an estrogen that inhibits 5alpha-reductase and has potential in the study of androgenetic alopecia.

5α-reductase-IN-1 is a potent inhibitor of the enzyme 5α-reductase. This compound is primarily employed in research studies to investigate its potential efficacy in treating patterned alopecia. It is commonly used in combination with minoxidil, a well-known treatment for hair loss.

Itaconic acid prodrug-1 (Compound P2) is an orally active prodrug of Itaconic acid that efficiently delivers Itaconic acid to skin tissues upon oral administration. It exhibits immunomodulatory effects, significantly inhibiting Poly(I:C) IFNγ-induced inflammatory cytokines in human epidermal keratinocytes. Itaconic acid prodrug-1 is useful for research into alopecia areata and other inflammatory skin conditions.

Diphenylcyclopropenone (DPCP) is a topical drug used to treat alopecia areata, alopecia totalis, and refractory warts. Diphencyprone acts as a local stimulator that triggers an immune response against the action of autoreactive cells.

Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor with an IC50 of 4.2 nM for type II 5α-reductase, demonstrating approximately 100-fold higher affinity for type II than type I. Finasteride acetate can be used for research on benign prostatic hyperplasia (BPH) and androgenic alopecia [1] [2] [3].

GW 9578 is a selective and potent PPARα agonist with potent lipid-lowering activity for the study of psoriasis, arthritis, alopecia, asthma and type I diabetes.

PF 00277343, a thyroid receptor agonist, is used for the treatment of androgenetic alopecia.

(Rac)-PF-998425 is a potent, selective, nonsteroidal androgen receptor (AR) antagonist with IC50 values of 26 nM in AR binding assays and 90 nM in cellular assays, respectively. This compound shows promise for investigating androgenetic alopecia.

TP0427736 hydrochloride is a novel and selective ALK5 inhibitor with an IC50 of 2.72 nM, capable of inhibiting Smad2 3 phosphorylation in A549 cells, reducing TGF-β-induced growth inhibition of human root sheath cells, and prolonging the anagen phase of mouse hair follicles.

GLF (H-Gly-Leu-Phe-OH), a tripeptide isolated from α-lactalbumin with immunostimulatory properties, prevents alopecia, epidermal thickening, and adipocyte layer thinning induced by the anticancer agent Etoposide [1].

5-Androstenetriol, a steroid and active metabolite of dehydroepiandrosterone (DHEA), demonstrates significant therapeutic effects. Administered at 0.75 mg/25 g body weight, it mitigates radiation-induced mortality and facilitates hematopoietic recovery from surviving stem cells in mice. Moreover, a dosage of 40 mg/kg enhances survival rates in rats subjected to surgical trauma-induced sepsis. Additionally, elevated urinary levels of 5-androstenetriol are observed in women suffering from androgenic alopecia.

Alpha-Estradiol (Standard) is the standard substance of Alpha-Estradiol, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Alpha-Estradiol (Epiestradiol) is an estrogen that inhibits 5alpha-reductase and has potential in the study of androgenetic alopecia.